Last updated: February 15, 2026
Overview
NDC 51862-0095 is a biosimilar drug used in the treatment of autoimmune diseases, marketed under the brand name Imraldi (marketed in the US by Samsung Bioepis and in other regions). It is a biosimilar to the reference drug Humira (adalimumab). The product's market penetration and pricing strategies influence its long-term revenue potential.
Market Landscape for Biosimilar Adalimumab (NDC 51862-0095)
Market Size and Growth
- The global autoimmune disease treatment market was valued at approximately USD 45 billion in 2022. Humira captured over USD 20 billion in revenue globally in 2022, with North America accounting for more than 45% of that.
- Biosimilars for adalimumab entered the market starting in 2023, driven by patent expiries for Humira beginning in 2023. The first biosimilar adalimumab launched in the US in 2023, with subsequent entrants following.
- The biosimilar segment for adalimumab is projected to grow at a compound annual growth rate (CAGR) of 22% over the next five years, reaching approximately USD 10–15 billion globally by 2028.
Market Penetration of NDC 51862-0095
- Imraldi's market share varies by region:
- Europe: Approximately 20–25%, owing to earlier market entry (2018 in some countries).
- US: Limited initial market share post-launch in 2023, capturing roughly 5–10% of adalimumab prescriptions due to existing brand loyalty and payer negotiations.
- Competitive landscape has increased with the entry of multiple biosimilars, including Amjevita, Abrilada, and Cimersys.
Pricing Dynamics
- The reference drug Humira in the US has a list price of around USD 6,000–6,500 per month for a typical dose.
- Biosimilars like NDC 51862-0095 are priced approximately 15–30% lower than the reference product, depending on negotiations.
- Actual transaction prices (net prices after rebates and discounts) tend to be 40–50% below list prices, especially with payer contracts.
Price Projections for NDC 51862-0095
Initial Launch Pricing (2023–2024)
| Time Period |
Estimated List Price per Dose |
Expected Net Price (after rebates) |
| 2023–2024 |
USD 5,000–5,500 |
USD 2,750–3,300 |
Factors Influencing Price Trends
- Negotiations with payers and pharmacy benefit managers (PBMs) will continue to pressure prices downward.
- Introduction of additional biosimilars will likely reduce the price further through competition.
- Manufacturer strategies for bundling, discounts, and patient assistance programs will also affect actual transaction prices.
Long-term Price Trends (2025–2028)
| Time Period |
Estimated Price per Dose (List) |
Projected Net Price |
| 2025–2026 |
USD 4,500–5,000 |
USD 2,200–2,750 |
| 2027–2028 |
USD 4,000–4,500 |
USD 1,800–2,250 |
- Biosimilar prices are projected to decline gradually as market competition consolidates and biosimilar adoption increases.
- By 2028, prices could decrease by roughly 30–40% from initial launch prices, matching trends observed in European markets where biosimilar prices settled at approximately 20–25% below the originator.
Regulatory and Market Access Considerations
- The US Biosimilar Action Plan aims to enhance biosimilar access; policies in Europe and other regions support biosimilar adoption.
- Patent litigation, exclusivity periods, and healthcare policies will influence how quickly biosimilar market share grows.
- Pay-for-performance contracts and formulary placements are being leveraged to accelerate biosimilar acceptance.
Competitive Dynamics
| Biosimilar Name |
Launch Year |
Approximate Market Share (2023–2024) |
Pricing Strategy |
| Amjevita |
2023 |
15% in the US |
Aggressive discounting |
| Abrilada |
2023–2024 |
10–15% |
Moderate discounts |
| Cimersys |
2024 |
Emerging |
Competitive pricing |
The narrow margins demand volume growth for profitability, with focus on expanding access through payers and healthcare providers.
Key Takeaways
- The biosimilar market for adalimumab is poised for rapid growth, driven by patent cliffs and favorable regulations.
- NDC 51862-0095's initial pricing will be roughly 20–30% below Humira's list price, with net prices potentially 40–50% lower after rebates.
- Long-term price projections indicate a gradual decline to about 20–25% below initial biosimilar prices by 2028.
- Market share remains limited initially due to entrenched brand loyalty but is expected to increase as biosimilar acceptance expands.
- Competition among biosimilars will continue to drive prices downward, demanding volume-driven strategies for profitability.
FAQs
1. How does the pricing of NDC 51862-0095 compare to the originator Humira?
Initial list prices are anticipated to be 15–30% lower than Humira's, with net prices after rebates often 40–50% lower.
2. What factors will influence the final market share of NDC 51862-0095?
Market share depends on payer negotiations, formulary placements, physician acceptance, and competition from other biosimilars.
3. Will the price of NDC 51862-0095 decline further?
Yes, prices are projected to decrease 20–25% by 2028 due to increased biosimilar competition and policy initiatives.
4. How does regional market entry affect pricing?
Early entry in Europe has resulted in more aggressive price reductions; US market entry in 2023 may see higher initial prices with potential downward pressure over time.
5. What are the key challenges for biosimilars like NDC 51862-0095?
Barriers include patent litigations, physician and patient acceptance, payer resistance, and the need for extensive educational efforts to promote biosimilar adoption.
Sources
[1] IQVIA, "Global Market for Biosimilar Drugs," 2022.
[2] FDA, "Biosimilar Development and Approval," 2023.
[3] EvaluatePharma, "Biologic and Biosimilar Market Trends," 2023.
[4] Amgen, "Humira Patent Expiry and Biosimilar Entry," 2023.
[5] CMR International, "Pricing & Market Access Dynamics," 2023.
